Cathelicidins as novel therapeutic antiviral agents in Rhinovirus infection

  We have identified the human cathelicidn LL-37 as having potent direct antiviral activity against human rhinovirus (HRV), together with the capacity to alter death pathways in HRV-infected cells, as a potential host defence mechanism. We propose to characterise the mechanism by which LL-37 exerts antiviral effects towards HRV, and to access the potential for both exogenous LL-37 and Vitamin D to be used as antiviral therapeutics in this infection.

  • Start Date:

    1 May 2015

  • End Date:

    30 June 2017

  • Activity Type:

    Research

  • Funder:

    Chief Scientists Office

  • Value:

    £163152

Project Team